Encapsulate Pharma becomes Distribution Partner for Merz Therapeutics in the Australian Market
As of August 1st 2020, Encapsulate Pharma will commence as the Distribution Partner for Merz Therapeutics in the Australian market. This will involve the Marketing, Sales and Distribution of Merz Pharmaceuticals innovative Incobotulinum Toxin Type A (Xeomin®) in all approved Therapeutic Indications. Founder and Managing Director of Encapsulate Pharma, Jay Calder, has spent the last three and a half years in Germany which included working as the Head of Distribution Partner Business – Xeomin® in EMEA. It was there that he was responsible for Distribution Partner Business for Xeomin® in over 27 markets. Now back in Australia and as Managing Director of Encapsulate Pharma he plans to grow and improve the support for Physicians in treating patients with movement disorders.
“We are proud to represent Merz Therapeutics in Australia, initially with their innovative Incobotulinum Toxin Type A (Xeomin®). However, botulinum toxin treatment is a skill not a pill, and we look forward to supporting Physicians in improving outcomes for their patients.”